Bifogade filer
AcouSort secures working capital through H1, 2025
Prenumeration
Beskrivning
| Land | Sverige |
|---|---|
| Lista | First North Stockholm |
| Sektor | Hälsovård |
| Industri | Bioteknik |
Through a consortium consisting of the company's management, board of directors, founders and major shareholders, AcouSort has received loan guarantees of approximately SEK 4.5 million. Together with current cash position and known future revenues, the loan guarantees secure the execution of AcouSort's planned activities into Q3 of 2025. AcouSort will now work to establish the best possible financing for the company’s next development phase.
The loan facility gives AcouSort the right to request disbursement of all or part of the loan from the lenders if the company deems that there is a need for financing. Unless the parties have agreed otherwise, the disbursed part of the loan must be repaid together with accrued interest no later than 31 December 2025. However, AcouSort has the right to freely repay all or part of the loan early. The setup fee for the loan agreement is 1% and the interest to be paid if the loans are drawn is in line with current market conditions.
“Our current cash position including known future revenues and royalties from Werfen will take us well into Q2. The reason for securing loan guarantees at this stage is to provide AcouSort with ample time to establish the best possible financing partnerships going forward. For me it is gratifying to see that the company’s management and board alongside major shareholders share my conviction of the company’s great potential within advanced healthcare,” says AcouSort's CEO Torsten Freltoft.